×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
FATE – fate therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
FATE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/19
08:20 am
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Medium
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
11/18
04:43 pm
fate
Fate Therapeutics, Inc. (NASDAQ: FATE) was upgraded by analysts at Bank of America Co. from an "underperform" rating to a "neutral" rating.
Medium
Report
Fate Therapeutics, Inc. (NASDAQ: FATE) was upgraded by analysts at Bank of America Co. from an "underperform" rating to a "neutral" rating.
11/18
08:11 am
fate
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence [Yahoo! Finance]
Medium
Report
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence [Yahoo! Finance]
11/18
08:07 am
fate
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence [Yahoo! Finance]
Low
Report
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence [Yahoo! Finance]
11/18
08:05 am
fate
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
Medium
Report
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
11/18
08:00 am
fate
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
Medium
Report
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
11/15
06:59 am
fate
Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates [Yahoo! Finance]
Medium
Report
Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates [Yahoo! Finance]
11/14
06:59 am
fate
Fate Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Medium
Report
Fate Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
07:50 pm
fate
Form SC 13G/A FATE THERAPEUTICS INC Filed by: Point72 Asset Management, L.P.
Medium
Report
Form SC 13G/A FATE THERAPEUTICS INC Filed by: Point72 Asset Management, L.P.
11/12
04:04 pm
fate
Form 10-Q FATE THERAPEUTICS INC For: Sep 30
Medium
Report
Form 10-Q FATE THERAPEUTICS INC For: Sep 30
11/12
04:02 pm
fate
Form 8-K FATE THERAPEUTICS INC For: Nov 12
Medium
Report
Form 8-K FATE THERAPEUTICS INC For: Nov 12
11/8
05:31 pm
fate
Form SC 13G/A FATE THERAPEUTICS INC Filed by: BlackRock, Inc.
Medium
Report
Form SC 13G/A FATE THERAPEUTICS INC Filed by: BlackRock, Inc.
10/25
09:37 pm
fate
Form SC 13G/A FATE THERAPEUTICS INC Filed by: Boxer Capital Management, LLC
Medium
Report
Form SC 13G/A FATE THERAPEUTICS INC Filed by: Boxer Capital Management, LLC
10/21
04:12 pm
fate
Form SC 13G/A FATE THERAPEUTICS INC Filed by: BlackRock, Inc.
Low
Report
Form SC 13G/A FATE THERAPEUTICS INC Filed by: BlackRock, Inc.
8/30
04:22 pm
fate
Form 8-K FATE THERAPEUTICS INC For: Aug 26
High
Report
Form 8-K FATE THERAPEUTICS INC For: Aug 26
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/7
Fate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever Universal, Off-the-shelf, iPSC-derived NK Cell Cancer Immunotherapy Programs
41.3%
12/14 Edited Transcript of FATE earnings conference call or presentation 5-Nov-19 10:00pm GMT [Yahoo! Finance News] 10.7%
4/2 Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update 9.2%
11/6 Fate Therapeutics Inc (NASDAQ: FATE) was downgraded by analysts at Mizuho to a "buy" rating. 8.7%
2/12 Fate Therapeutics Inc (NASDAQ: FATE) had its "overweight" rating re-affirmed by analysts at Wells Fargo & Co. They now have a $34.00 price target on the stock, up previously from $24.00. 8.5%
3/3 Fate Therapeutics Inc (NASDAQ: FATE) had its price target raised by analysts at Roth Capital from to . 7.9%
4/8 Fate Therapeutics Inc (NASDAQ: FATE) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $27.00 price target on the stock. 7.8%
10/19 Have Fate Therapeutics, Inc. (NASDAQ:FATE) Insiders Been Selling Their Stock? [Yahoo! Finance News] 7.6%
4/14 Fate Therapeutics Inc (NASDAQ: FATE) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 7.4%
4/4 Growth Investors: Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 13% [Yahoo! Finance News] 7.1%
12/14 Edited Transcript of FATE earnings conference call or presentation 5-Nov-19 10:00pm GMT [Yahoo! Finance News] 10.7%
4/2 Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update 9.2%
11/6 Fate Therapeutics Inc (NASDAQ: FATE) was downgraded by analysts at Mizuho to a "buy" rating. 8.7%
2/12 Fate Therapeutics Inc (NASDAQ: FATE) had its "overweight" rating re-affirmed by analysts at Wells Fargo & Co. They now have a $34.00 price target on the stock, up previously from $24.00. 8.5%
3/3 Fate Therapeutics Inc (NASDAQ: FATE) had its price target raised by analysts at Roth Capital from to . 7.9%
4/8 Fate Therapeutics Inc (NASDAQ: FATE) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $27.00 price target on the stock. 7.8%
10/19 Have Fate Therapeutics, Inc. (NASDAQ:FATE) Insiders Been Selling Their Stock? [Yahoo! Finance News] 7.6%
4/14 Fate Therapeutics Inc (NASDAQ: FATE) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 7.4%
4/4 Growth Investors: Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 13% [Yahoo! Finance News] 7.1%
TOP News Decliners
11/6
Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha]
-14.7%
3/3 Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -12.6%
4/3 Fate Therapeutics Inc (NASDAQ: FATE) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $40.00 price target on the stock. -11.8%
8/14 Fate Therapeutics Announces Issuance of Foundational U.S. Patent Covering iPSC-derived CAR T Cells -10.1%
3/31 Form 4 FATE THERAPEUTICS INC For: Mar 30 Filed by: RASTETTER WILLIAM H -9.0%
3/12 Fate Therapeutics Inc (NASDAQ: FATE) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -8.3%
4/28 Fate Therapeutics Inc (NASDAQ: FATE) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.4%
5/30 Fate Therapeutics Inc (NASDAQ: FATE) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock. -7.1%
9/30 Fate Therapeutics Inc (NASDAQ: FATE) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock. -6.8%
8/6 Form 10-Q FATE THERAPEUTICS INC For: Jun 30 -6.5%
3/3 Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -12.6%
4/3 Fate Therapeutics Inc (NASDAQ: FATE) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $40.00 price target on the stock. -11.8%
8/14 Fate Therapeutics Announces Issuance of Foundational U.S. Patent Covering iPSC-derived CAR T Cells -10.1%
3/31 Form 4 FATE THERAPEUTICS INC For: Mar 30 Filed by: RASTETTER WILLIAM H -9.0%
3/12 Fate Therapeutics Inc (NASDAQ: FATE) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -8.3%
4/28 Fate Therapeutics Inc (NASDAQ: FATE) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.4%
5/30 Fate Therapeutics Inc (NASDAQ: FATE) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock. -7.1%
9/30 Fate Therapeutics Inc (NASDAQ: FATE) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock. -6.8%
8/6 Form 10-Q FATE THERAPEUTICS INC For: Jun 30 -6.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: